Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1
about
Intracellular Cleavage of the Cx43 C-Terminal Domain by Matrix-Metalloproteases: A Novel Contributor to Inflammation?Connexin's Connection in Breast Cancer Growth and ProgressionConnexin and pannexin channels in cancer.Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cellsGap junctions and cancer: communicating for 50 years.Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.Mechanism of Action of the Anti-Inflammatory Connexin43-Mimetic Peptide JM2.Connexin channel and its role in diabetic retinopathy.Connexin 43 in the development and progression of breast cancer: What's the connection? (Review).Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas.Modulation of gap junction-associated Cx43 in neural stem/progenitor cells following traumatic brain injury.Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer.Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration.The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response.Genetics: Transcribing for the enemy.
P2860
Q26783641-242E53B4-ECB8-49BB-AB91-A559EF5D4924Q28073076-5B9ED6CE-0F73-4C81-B5AD-20DFBB5DDD1CQ36031173-179BEF2C-AF9A-47DB-B800-E3E73F9976CCQ36185088-54C78CE4-3E32-4136-B0B7-345213AC87C9Q37613777-E3F35AEE-FE79-4377-8E44-3C56A7D95811Q37690877-A792103D-EB97-4201-9188-C1BA1A89D596Q38682090-BF4C102A-294F-4F03-ACE9-410E6042C8E3Q39365499-4EB18853-C251-4FF5-88F8-92275896B59EQ41389665-291DC3C3-C5F0-4DE2-A030-96B8D2E4F8A1Q42120003-4F5B3928-8452-49F5-B7C2-1D4A70055BDEQ45062026-6B078140-A1C4-43F7-B9BA-4C3D7A77C93CQ45073978-D3C8E8A3-C2D3-403D-8D67-7444AF979945Q47220416-94D8CABE-C93E-4D21-8A7F-6518655D600CQ53699942-47A6BA6E-0C6A-4622-88EE-7EC51C319A55Q54540610-C507CD1C-F504-4CED-A25C-1AD9FD716FF8
P2860
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@ast
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@en
type
label
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@ast
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@en
prefLabel
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@ast
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@en
P2093
P2860
P1433
P1476
Targeting connexin 43 with α-c ...... clinical implication for ACT1
@en
P2093
Christina L Grek
Elizabeth S Yeh
Gautam S Ghatnekar
Jaclynn S Bruce
Melissa A Abt
P2860
P2888
P356
10.1186/S12885-015-1229-6
P407
P577
2015-04-03T00:00:00Z
P5875
P6179
1002002834